# Phase III Study to Investigate the Safety and Efficacy of Fermagate and Sevelamer Hydrochloride

> **NCT00844662** · PHASE3 · TERMINATED · sponsor: **Ineos Healthcare Limited** · enrollment: 1000 (estimated)

## Conditions studied

- Chronic Kidney Failure

## Interventions

- **DRUG:** Fermagate
- **DRUG:** Sevelamer hydrochloride

## Key facts

- **NCT ID:** NCT00844662
- **Lead sponsor:** Ineos Healthcare Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-07
- **Primary completion:** 2011-09
- **Final completion:** 2011-10
- **Target enrollment:** 1000 (ESTIMATED)
- **Last updated:** 2010-10-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00844662

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00844662, "Phase III Study to Investigate the Safety and Efficacy of Fermagate and Sevelamer Hydrochloride". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00844662. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*